BITTER PILL: John Castellani, president and CEO of PhRMA, cautions against cutting from 12 years to seven the length of a patent on a company's new drug. (J.M. Eddins Jr./The Washington Times)

BITTER PILL: John Castellani, president and CEO of PhRMA, cautions against cutting from 12 years to seven the length of a patent on a company's new drug. (J.M. Eddins Jr./The Washington Times)